drugset
drugset / Trial / NCT05061693

A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis

NCT05061693 ↗

Phase 2 Completed 146 enrolled Incyte Corporation
RandomizedParallel-groupTriple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of INCB054707 in participants with prurigo nodularis over a 16-week double-blind placebo-controlled treatment period, followed by a 24 -week single blind extension period.

Timeline

Start
2021-11-04
Primary completion
2023-08-11
Completion
2024-02-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Povorcitinib Small molecule — Oral

Indications

prurigo nodularis